Effects of Oral Adsorbent AST-120 (Kremezin(R)) on the Progression of Chronic Kidney Disease.
- Author:
Yong Kyu LEE
1
;
Sung Jin MOON
;
Hye Rim AN
;
Jwa Kyung KIM
;
Sung Chang BAE
;
Beom Seok KIM
;
Hyeong Cheon PARK
;
Sung Kyu HA
Author Information
1. Department of Internal medicine, Yonsei University College of Medicine, Seoul, Korea. Hask1951@yuhs.ac
- Publication Type:Original Article
- Keywords:
AST-120;
Chronic renal failure;
Glomerular filtration rate
- MeSH:
Carbon;
Diabetes Mellitus;
Gastrointestinal Tract;
Glomerular Filtration Rate;
Humans;
Indican;
Indoles;
Kidney Failure, Chronic;
Korea;
Male;
Oxides;
Renal Insufficiency, Chronic
- From:Korean Journal of Nephrology
2010;29(4):450-457
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: AST-120 is known to delay progression of chronic kidney disease (CKD) when combined with other proven therapy. AST-120 is an oral adsorbent for uremic toxin, such as indoxyl sulfate from the gastrointestinal tract. There have been a lot of studies to show its effect in other countries, but there are few studies done in Korea yet. METHODS: 195 patients were included in the study (mean age, 64+/-14 years; diabetes mellitus (DM), 104 patients; male, 130 patients). The patients with CKD who started AST-120 and maintained the medication for at least 6 months were enrolled. The patients' laboratory results for 6 months before and after administrating AST-120 was surveyed. Then the rate of patients' renal functional deterioration was compared before and after AST-120. In addition, adverse effects during the medication were surveyed. RESULTS: There were no statistically significant differences in laboratory data between before and after AST-120 administration. But, after administrating AST-120, the renal deterioration slope has blunted significantly from -0.0123+/-0.0318 to -0.0013+/-0.0184 dL/mg/month (p<0.01) in 1/sCr and from -1.1423+/-2.3906 to 0.0639+/-1.3825 ml/min/1.73m2/month (p<0.01) in estimated glomerular filtration rate (eGFR). There were no differences between DM and non-DM patients in the effect of AST-120, as well as ages over 70 and below 70. There were no serious adverse effects during medication. CONCLUSION: This study showed that AST-120 had additive effect on retarding the CKD progression when combined with established therapy regardless of DM and ages without serious adverse effects.
